Merck & Co., Inc. Release: FDA Accepts Two Supplemental New Drug Applications To Expand the U.S. Labeling For JANUVIA(TM)

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck & Co., Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for standard review two supplemental New Drug Applications (sNDAs) for JANUVIA™ (sitagliptin), and the Company expects FDA action on both sNDAs by mid-October.